Evidence map›Paper›PMID 39418671›Full record

ArticleJournal of proteome research2024

Multiomics Studies on Metabolism Changes in Alcohol-Associated Liver Disease.

Liqing He, Raobo Xu, Xipeng Ma, Xinmin Yin, Eugene Mueller, Wenke Feng, Michael Menze, Seongho Kim, Craig J McClain, Xiang Zhang

Abstract read
In one paragraph

Article in Journal of proteome research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Liqing HeDepartment of Chemistry, University of Louisville, Louisville, Kentucky 40208, United States.ORCID 0000-0002-0428-814X
Raobo XuDepartment of Chemistry, University of Louisville, Louisville, Kentucky 40208, United States.ORCID 0000-0002-7178-8961
Xipeng MaDepartment of Chemistry, University of Louisville, Louisville, Kentucky 40208, United States.
Xinmin YinDepartment of Chemistry, University of Louisville, Louisville, Kentucky 40208, United States.
Eugene MuellerDepartment of Chemistry, University of Louisville, Louisville, Kentucky 40208, United States.
Wenke FengUniversity of Louisville Alcohol Research Center, University of Louisville, Louisville, Kentucky 40208, United States.
Michael MenzeDepartment of Biology, University of Louisville, Louisville, Kentucky 40208, United States.ORCID 0000-0003-1072-5462
Seongho KimDepartment of Oncology, Wayne State University, Detroit, Michigan 48201, United States.
Craig J McClainUniversity of Louisville Alcohol Research Center, University of Louisville, Louisville, Kentucky 40208, United States.
Xiang ZhangDepartment of Chemistry, University of Louisville, Louisville, Kentucky 40208, United States.ORCID 0000-0003-1102-6313

Funding

Role of oxidized linoleic acid metabolites in the pathogenesis of alcoholic liver diseaseP20GM113226 · NIGMS · UNIVERSITY OF LOUISVILLE · PI HOOD, JOSHUA L. · 2016 to 2025
$24.1M
The Role of Nutrition in the Development/Progression of Alcohol-Induced Organ InjuryP50AA024337 · NIAAA · UNIVERSITY OF LOUISVILLE · PI CRAIG J. MCCLAIN · 2016 to 2026
$17.9M
Integrated therapies for alcohol use and ALD (ITAALD) Network -UofL Clinical CenterU01AA026980 · NIAAA · UNIVERSITY OF LOUISVILLE · PI CRAIG J. MCCLAIN, Ashwani K Singal · 2018 to 2026
$2.9M
Intestine FXR activation by LGG-derived nanoparticles in alcohol-associated liver diseaseR01AA030424 · NIAAA · UNIVERSITY OF LOUISVILLE · PI WENKE FENG · 2022 to 2026
$2.6M
Ultra Performance Liquid Chromatography High Resolution High Mass Accuracy Mass SpectrometerS10OD020106 · OD · UNIVERSITY OF LOUISVILLE · PI ZHANG, XIANG · 2015 to 2015
$600k
RNA Modification Changes in Alcohol-Associated Liver DiseaseR21AA031563 · NIAAA · UNIVERSITY OF LOUISVILLE · PI HE, LIQING · 2024 to 2025
$400k
Pilot Trial UO1 DUR-928U01AA026934 · NIAAA · UNIVERSITY OF LOUISVILLE · PI MCCLAIN, CRAIG J. · 2018 to 2022
$356k
BLRD VA I01 BX002996NIAAA NIH HHS P50 AA024337NIAAA NIH HHS R01 AA030424NIAAA NIH HHS R21 AA031563NIAAA NIH HHS U01 AA026934NIAAA NIH HHS U01 AA026980NIGMS NIH HHS P20 GM113226NIH HHS S10 OD020106
6 · The paper itself

Abstract

Metabolic dysfunction in the liver represents a predominant feature in the early stages of alcohol-associated liver disease (ALD). However, the mechanisms underlying this are only partially understood. To investigate the metabolic characteristics of the liver in ALD, we did a relative quantification of polar metabolites and lipids in the liver of mice with experimental ALD using untargeted metabolomics and untargeted lipidomics. A total of 99 polar metabolites had significant abundance alterations in the livers of alcohol-fed mice. Pathway analysis revealed that amino acid metabolism was the most affected by alcohol in the mouse liver. Metabolites involved in glycolysis and the TCA cycle were decreased, while glycerol 3-phosphate (G3P) and long-chain fatty acids were increased. Relative quantification of lipids unveiled an upregulation of multiple lipid classes, suggesting that alcohol consumption drives metabolism toward lipid synthesis. Results from enzyme expression and activity detection indicated that the decreased activity of mitochondrial glycerol 3-phosphate dehydrogenase contributed to the disordered metabolism.

Indexed as

Lipid MetabolismLipidomicsLiverLiver Diseases, AlcoholicMetabolomicsAmino AcidsAnimalsCitric Acid CycleEthanolFatty AcidsGlycerolphosphate DehydrogenaseGlycerophosphatesGlycolysisMaleMetabolomeMicealpha-glycerophosphoric acidAmino AcidsEthanolFatty AcidsGlycerolphosphate DehydrogenaseGlycerophosphatesalcohol-associated liver diseaselipidomicsmetabolic dysfunctionmetabolomicsmitochondrial glycerol 3-phosphate dehydrogenase

Identifiers

PMID39418671
PMCPMC12207657

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.